An Alzheimer's vaccine that targets beta-amyloid.
Alzheimer's Donation
Donate Online Now
.
The Austrian company Affiris GmbHproject is part of the sixth EU Framework Programme and is seeking to develop an Alzheimer's vaccine that targets specific types of beta-amyloid, the causative agent of Alzheimer's disease. "Alzheimer's is caused by deposits of beta-amyloid peptides. These deposits – also known as plaques – are formed when parts of a human protein detach from the cell membrane of nerve cells and clump together, Dr. Frank Mattner, Project Manager and CSO of Affiris GmbH, explains.
“A high proportion of these peptides, the so-called beta-amyloids, consist of 40 or 42 amino acids. The first vaccine developed by Affiris targets precisely these types of peptides and helps to break down the plaques." It was a technology from Affiris GmbH, that proved decisive in securing approval for the project. This technology enables scientists to get round a key problem posed by vaccines against degenerated human proteins such as beta-amyloid – the development of autoimmune reaction.
By selecting the correct peptides for the vaccine, Affiris GmbH's mimotope technology enables a precise immune reaction to be implemented against only the degenerated form of the protein, and for this to be done without attacking the natural form. This principle has already been proven in the first vaccine developed by Affiris. "The exceptional approval rating the Framework Programme's panel of independent experts gave the MimoVax project – 29 out of a possible 30 points – is, of course, also a great vote of confidence in Affiris' mimotope technology. And, actually, MIG-Fonds in Germany have already invested in this Affiris technology, thereby enabling us to reach the current stage of development for our first Alzheimer's vaccine.
“This will be used on the first patients in the coming months. Overall, this broad financial support demonstrates wide-ranging confidence in the use of mimotope technology as an efficient strategy for vaccinating against human rogue proteins." During the MimoVax project, both pre-clinical and the first clinical phases of development for the new vaccine will be carried out over the next three years.
Alzheimer's Donation
Donate Online Now
.
The Austrian company Affiris GmbHproject is part of the sixth EU Framework Programme and is seeking to develop an Alzheimer's vaccine that targets specific types of beta-amyloid, the causative agent of Alzheimer's disease. "Alzheimer's is caused by deposits of beta-amyloid peptides. These deposits – also known as plaques – are formed when parts of a human protein detach from the cell membrane of nerve cells and clump together, Dr. Frank Mattner, Project Manager and CSO of Affiris GmbH, explains.
“A high proportion of these peptides, the so-called beta-amyloids, consist of 40 or 42 amino acids. The first vaccine developed by Affiris targets precisely these types of peptides and helps to break down the plaques." It was a technology from Affiris GmbH, that proved decisive in securing approval for the project. This technology enables scientists to get round a key problem posed by vaccines against degenerated human proteins such as beta-amyloid – the development of autoimmune reaction.
By selecting the correct peptides for the vaccine, Affiris GmbH's mimotope technology enables a precise immune reaction to be implemented against only the degenerated form of the protein, and for this to be done without attacking the natural form. This principle has already been proven in the first vaccine developed by Affiris. "The exceptional approval rating the Framework Programme's panel of independent experts gave the MimoVax project – 29 out of a possible 30 points – is, of course, also a great vote of confidence in Affiris' mimotope technology. And, actually, MIG-Fonds in Germany have already invested in this Affiris technology, thereby enabling us to reach the current stage of development for our first Alzheimer's vaccine.
“This will be used on the first patients in the coming months. Overall, this broad financial support demonstrates wide-ranging confidence in the use of mimotope technology as an efficient strategy for vaccinating against human rogue proteins." During the MimoVax project, both pre-clinical and the first clinical phases of development for the new vaccine will be carried out over the next three years.
posted by Valery Yermalitsky at
7:47 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home